About this item:

75 Views | 38 Downloads

Author Notes:

James E Squires MD, MS.

Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, One Children’s Hospital Drive, 6th Floor FP, 4401 Penn Avenue, Pittsburgh PA 15224.

Phone: 412-692-5180

Fax: 412-692-7355

James. Squires2@chp.edu

Subjects:

Research Funding:

This work was supported by U01 grants from the National Institute of Diabetes, Digestive and Kidney Diseases (DK 62445 [Mount Sinai School of Medicine], DK 62497 [Cincinnati Children’s Hospital Medical Center], DK 62470 [Children’s Healthcare of Atlanta], DK 62481 [The Children’s Hospital of Philadelphia], DK 62456 [The University of Michigan], DK 84536 [Riley Hospital for Children], DK 84575 [Seattle Children’s Hospital], DK 62500 [UCSF Children’s Hospital], DK 62503 [Johns Hopkins School of Medicine], DK 62466 [Children’s Hospital of Pittsburgh of UPMC], DK 62453 [University of Colorado Denver], DK 62452 [Washington University School of Medicine], DK 84538 [Children’s Hospital Los Angeles], DK 62436 [Ann & Robert H Lurie Children’s Hospital of Chicago], DK103149 [Texas Children’s Hospital], DK103135 [The Hospital for Sick Children], DK103140 [University of Utah]).

In addition, the project described was supported by National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (NCATS CTSA) grants: University of Colorado UL1 TR002535, Cincinnati Children’s Hospital Medical Center UL1 TR000077, UCSF Children’s Hospital UL1 TR001872, Indiana University Hospital for Children UL1 TR001108, Children’s Hospital of Pittsburgh of UPMC UL1 TR001857, The Children’s Hospital of Philadelphia UL1 TR001878, Seattle Children’s Hospital UL1 TR000423 and UL1 RR025014, Children’s Healthcare of Atlanta UL1 TR000454, Children’s Hospital of Los Angeles UL1TR00130.

KFM reports research support <$10K: Gilead, Shire/Mirum, Merck and consulting for Gilead. No additional support for this work; JPM reports funding from Abbvie, Gillead, Mirum for other studies not related to this work. VLN reports consulting fee or honorarium and support for travel to meetings for the study or other purposes. PR reports grant support from the NIH; VLN reports consulting fee or honorarium and support for travel to meetings for the study or other purposes.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Gastroenterology & Hepatology
  • Nutrition & Dietetics
  • Pediatrics
  • chronic liver disease
  • cognitive
  • pediatric
  • QUALITY-OF-LIFE
  • NEUROCOGNITIVE OUTCOMES
  • TRANSPLANTATION
  • INFANTS
  • GROWTH

Neurodevelopmental Outcomes in Preschool and School Aged Children With Biliary Atresia and Their Native Liver

Show all authors Show less authors

Journal Title:

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Volume:

Volume 70, Number 1

Publisher:

, Pages 79-86

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Objectives:The aim of the study was to assess neurodevelopmental outcomes among children with biliary atresia (BA) surviving with their native liver at ages 3 to 12 years and evaluate variables that associate with neurodevelopment.Methods:Participants (ages 3-12 years) in a prospective, longitudinal, multicenter study underwent neurodevelopmental testing with Weschler Preschool and Primary Scale of Intelligence, 3rd edition (WPPSI-III, ages 3-5 years) and Weschler Intelligence Scale for Children, 4th edition (WISC-IV, ages 6-12 years). Continuous scores were analyzed using Kolmogorov-Smironov tests compared with a normal distribution (mean = 100 ± 15). Effect of covariates on Full-Scale Intelligence Quotient (FSIQ) was analyzed using linear regression.Results:Ninety-three participants completed 164 WPPSI-III (mean age 3.9) and 51 WISC-IV (mean age 6.9) tests. WPPSI-III FSIQ (104 ± 14, P < 0.02), Verbal IQ (106 ± 14, P < 0.001), and General Language Composite (107 ± 16, P < 0.001) distributions were shifted higher compared with test norms. WISC-IV FSIQ (105 ± 12, P < 0.01), Perceptual Reasoning Index (107 ± 12, P < 0.01), and Processing Speed Index (105 ± 10, P < 0.02) also shifted upwards. In univariate and multivariable analysis, parent education (P < 0.01) was a significant predictor of FSIQ on WPPSI-III and positively associated with WISC-IV FSIQ. Male sex and higher total bilirubin and gamma glutamyl transferase (GGT) predicted lower WPPSI-III FSIQ. Portal hypertension was predictive of lower WISC-IV FSIQ.Conclusions:This cohort of children with BA and native liver did not demonstrate higher prevalence of neurodevelopmental delays. Markers of advanced liver disease (higher total bilirubin and GGT for age ≤5 years; portal hypertension for age ≥6) correlate with lower FSIQ and may identify a vulnerable subset of patients who would benefit from intervention.

Copyright information:

2020

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/rdf).
Export to EndNote